search
Back to results

Single Ascending Dose Study of Safety and Tolerability of SPH3127 Tablet in Chinese Healthy Volunteers

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
SPH3127
Sponsored by
Shanghai Pharmaceuticals Holding Co., Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy adults,age >=18 years.Single gender should no less than a third of total subjects in each group.
  • BMI should be18 to 24 kg/m2 (including threshold), allowing the lowest weight 50 kg (including threshold) for the male and 45 kg (including threshold) for the female.
  • understand details of significance, benefit, inconvenience and potential danger of the research program, voluntarily signed informed consent.

Exclusion Criteria:

  • during pregnancy, nursing mothers, and plans to test in the first 6 months (grant) pregnant;
  • abnormal results in physical examination, laboratory examination and have clinical significance (such as: liver function examination - aspartate aminotransferase (AST)/alanine aminotransferase (ALT) is more than 1.5 times of the upper limit of normal).
  • with cardiovascular, liver, kidney, gastrointestinal, nervous system, blood system and familial blood disease, thyroid dysfunction or abnormal mental illness;
  • has a history of drug allergy and allergic constitution;
  • took birth control pills within 6 weeks;
  • used any drugs (including Chinese herbal medicine) within 1 week;
  • participated in blood donation within 2 months ;
  • participated in any drug clinical trials (as subjects) within three months;
  • any positive result in virus serology check: human immunodeficiency virus antigen antibody (HIV Ag/Ab) 、hepatitis c virus (HCV) - IgG antibody to IgG, hepatitis b surface antigen (HBsAg) and treponema pallidum antibody (TP);
  • addicted to cigarettes, alcohol, drink coffee, strong tea and drug abuse;
  • researchers think that exists any unfavorable factors to participate in the test.

Sites / Locations

  • The capital medical university affiliated Beijing anzhen hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

25 mg SPH3127 tablet-Dose 1

50 mg SPH3127 tablet-Dose 2

100 mg SPH3127 tablet-Dose 3

200 mg SPH3127 tablet-Dose 4

400 mg SPH3127 tablet-Dose 5

800 mg SPH3127 tablet-Dose 6

Arm Description

6 Volunteers, Single dose of SPH3127 tablet, 25mg, po. 1 tablet. 2 Volunteers, Single dose of Placebo tablet, 25mg, po. 1 tablet.

6 Volunteers, Single dose of SPH3127 tablet, 50mg, po. 1 tablet. 2 Volunteers, Single dose of Placebo tablet, 50mg, po. 1 tablet.

6 Volunteers, Single dose of SPH3127 tablet, 100mg, po. 1 tablet. 2 Volunteers, Single dose of Placebo tablet, 100mg, po. 1 tablet.

6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 2 tablet. 2 Volunteers, Single dose of Placebo tablet, 100mg, po. 2 tablet.

6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 4 tablet. 2 Volunteers, Single dose of Placebo tablet, 100mg, po. 4 tablet.

6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 8 tablet. 2 Volunteers, Single dose of Placebo tablet, 100mg, po. 8 tablet.

Outcomes

Primary Outcome Measures

Assessment of safety parameters [adverse events, laboratory data, vital signs, and ECG]
adverse events, laboratory data, vital signs, and ECG et al.

Secondary Outcome Measures

Assessment of PK parameter 1 [Cmax]
Peak plasma concentration (Cmax)
Assessment of PD parameter 1 [Inhibition of Renion Activity (%)]
Inhibition of Renion Activity (%)
Assessment of PD parameter 2 [Blood pressure (mmHg)]
Blood pressure (mmHg)
Assessment of PK parameter 2 [tmax]
time to peak plasma concentration (tmax)
Assessment of PK parameter 3 [AUC]
Area under the plasma concentration versus time curve (AUC)

Full Information

First Posted
January 5, 2017
Last Updated
October 26, 2022
Sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT03128138
Brief Title
Single Ascending Dose Study of Safety and Tolerability of SPH3127 Tablet in Chinese Healthy Volunteers
Official Title
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Describe Pharmacokinetics/Pharmacodynamics, and the Safety and of SPH3127 Tablet in Chinese Healthy Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
November 2021
Overall Recruitment Status
Completed
Study Start Date
December 1, 2016 (Actual)
Primary Completion Date
June 30, 2018 (Actual)
Study Completion Date
July 30, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Shanghai Pharmaceuticals Holding Co., Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
To evaluate safety, tolerability and pharmacokinetics (PK) and pharmacodynamics (PD) characteristics of SPH3127 dose escalation, a single oral dose in Chines healthy volunteers. To explore the appropriate dose and provide the basis for the subsequent clinical trials.
Detailed Description
48 healthy volunteers will participate in this trial. Participants will be divided into 6 group, 25mg,50mg,100mg,200mg,400mg and 800mg. In each group, 6 participants will take SPH3127 tablet, while 2 participants will take placebo randomly. Safety data and PK/PD data will be collected as protocol described.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
48 (Actual)

8. Arms, Groups, and Interventions

Arm Title
25 mg SPH3127 tablet-Dose 1
Arm Type
Experimental
Arm Description
6 Volunteers, Single dose of SPH3127 tablet, 25mg, po. 1 tablet. 2 Volunteers, Single dose of Placebo tablet, 25mg, po. 1 tablet.
Arm Title
50 mg SPH3127 tablet-Dose 2
Arm Type
Experimental
Arm Description
6 Volunteers, Single dose of SPH3127 tablet, 50mg, po. 1 tablet. 2 Volunteers, Single dose of Placebo tablet, 50mg, po. 1 tablet.
Arm Title
100 mg SPH3127 tablet-Dose 3
Arm Type
Experimental
Arm Description
6 Volunteers, Single dose of SPH3127 tablet, 100mg, po. 1 tablet. 2 Volunteers, Single dose of Placebo tablet, 100mg, po. 1 tablet.
Arm Title
200 mg SPH3127 tablet-Dose 4
Arm Type
Experimental
Arm Description
6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 2 tablet. 2 Volunteers, Single dose of Placebo tablet, 100mg, po. 2 tablet.
Arm Title
400 mg SPH3127 tablet-Dose 5
Arm Type
Experimental
Arm Description
6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 4 tablet. 2 Volunteers, Single dose of Placebo tablet, 100mg, po. 4 tablet.
Arm Title
800 mg SPH3127 tablet-Dose 6
Arm Type
Experimental
Arm Description
6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 8 tablet. 2 Volunteers, Single dose of Placebo tablet, 100mg, po. 8 tablet.
Intervention Type
Drug
Intervention Name(s)
SPH3127
Intervention Description
Drug: SPH3127 Tablet Drug: Placebo Tablet
Primary Outcome Measure Information:
Title
Assessment of safety parameters [adverse events, laboratory data, vital signs, and ECG]
Description
adverse events, laboratory data, vital signs, and ECG et al.
Time Frame
10 days
Secondary Outcome Measure Information:
Title
Assessment of PK parameter 1 [Cmax]
Description
Peak plasma concentration (Cmax)
Time Frame
2 days
Title
Assessment of PD parameter 1 [Inhibition of Renion Activity (%)]
Description
Inhibition of Renion Activity (%)
Time Frame
2 days
Title
Assessment of PD parameter 2 [Blood pressure (mmHg)]
Description
Blood pressure (mmHg)
Time Frame
2 days
Title
Assessment of PK parameter 2 [tmax]
Description
time to peak plasma concentration (tmax)
Time Frame
2 days
Title
Assessment of PK parameter 3 [AUC]
Description
Area under the plasma concentration versus time curve (AUC)
Time Frame
2 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy adults,age >=18 years.Single gender should no less than a third of total subjects in each group. BMI should be18 to 24 kg/m2 (including threshold), allowing the lowest weight 50 kg (including threshold) for the male and 45 kg (including threshold) for the female. understand details of significance, benefit, inconvenience and potential danger of the research program, voluntarily signed informed consent. Exclusion Criteria: during pregnancy, nursing mothers, and plans to test in the first 6 months (grant) pregnant; abnormal results in physical examination, laboratory examination and have clinical significance (such as: liver function examination - aspartate aminotransferase (AST)/alanine aminotransferase (ALT) is more than 1.5 times of the upper limit of normal). with cardiovascular, liver, kidney, gastrointestinal, nervous system, blood system and familial blood disease, thyroid dysfunction or abnormal mental illness; has a history of drug allergy and allergic constitution; took birth control pills within 6 weeks; used any drugs (including Chinese herbal medicine) within 1 week; participated in blood donation within 2 months ; participated in any drug clinical trials (as subjects) within three months; any positive result in virus serology check: human immunodeficiency virus antigen antibody (HIV Ag/Ab) 、hepatitis c virus (HCV) - IgG antibody to IgG, hepatitis b surface antigen (HBsAg) and treponema pallidum antibody (TP); addicted to cigarettes, alcohol, drink coffee, strong tea and drug abuse; researchers think that exists any unfavorable factors to participate in the test.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
HONG MIAO
Organizational Affiliation
Shanghai Pharmaceuticals Holding Co., Ltd
Official's Role
Principal Investigator
Facility Information:
Facility Name
The capital medical university affiliated Beijing anzhen hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100029
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33653620
Citation
Jing S, Xu R, Yang K, Liu W, Zhang L, Ke Y, Xia G, Lin Y. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPH3127: A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial. Clin Ther. 2021 Apr;43(4):735.e1-735.e14. doi: 10.1016/j.clinthera.2021.01.025. Epub 2021 Feb 27.
Results Reference
derived

Learn more about this trial

Single Ascending Dose Study of Safety and Tolerability of SPH3127 Tablet in Chinese Healthy Volunteers

We'll reach out to this number within 24 hrs